Valuation: Precision BioSciences, Inc.

Market Cap 207M 180M 168M 153M 289M 19.77B 294M 1.97B 773M 9.9B 778M 761M 33.01B P/E 2026 *
-2.12x
P/E 2027 * -2.62x
Enterprise Value 207M 180M 168M 153M 289M 19.77B 294M 1.97B 773M 9.9B 778M 761M 33.01B EV / Sales 2026 *
16.4x
EV / Sales 2027 * 27.1x
Free-Float
93.72%
Yield 2026 *
-
Yield 2027 * -

Last Transcript: Precision BioSciences, Inc.

1 day+1.40%
1 week+2.54%
Current month+9.59%
1 month-10.83%
3 months-6.59%
6 months+93.43%
Current year+84.13%
1 week 7
Extreme 7
7.76
1 month 6.7
Extreme 6.7
8.96
Current year 3.53
Extreme 3.53
9.62
1 year 3.53
Extreme 3.53
9.62
3 years 3.53
Extreme 3.53
19.43
5 years 3.53
Extreme 3.53
431.4
10 years 3.53
Extreme 3.53
710.11
Manager TitleAgeSince
Chief Executive Officer 48 15/10/2021
Chief Tech/Sci/R&D Officer 53 26/01/2006
Director of Finance/CFO 45 01/08/2026
Director TitleAgeSince
Chairman 68 01/11/2020
Director/Board Member 65 10/03/2020
Director/Board Member 67 12/04/2021
Date Insider Type Main position Quantity % Market Cap.
01/08/26 Other

Chief Financial Officer

251,581 1.0451%
01/08/26 Other

Controller/Auditor

48,872 0.2030%
01/08/26 Other

Chief Technology Officer

236,188 0.9812%
Change 5-day change 1-year change 3-year change Capi.($)
+1.07%+2.54%+74.89%-51.91% 207M
-2.24%+0.07%+2.89%+13.68% 49.54B
+0.90%+5.05%+487.84%+590.91% 44.06B
-0.38%+9.41%+24.38%+75.55% 40.85B
-0.91%+2.20%+29.76%+9.60% 40.14B
+4.73%+13.29%+27.76%+54.22% 34.17B
-0.89%+1.82%+30.30%+125.31% 16.9B
-0.38%+4.09% - - 16.78B
-0.94%-0.63%+3.68%+20.08% 14B
+0.94%+8.96%+85.98%+30.98% 13.46B
Average +0.23%+7.29%+85.28%+96.49% 27.01B
Weighted average by Cap. +0.07%+7.39%+104.66%+137.53%

Financials

2026 *2027 *
Net sales 12.61M 10.93M 10.23M 9.34M 17.57M 1.2B 17.86M 120M 47.01M 602M 47.36M 46.33M 2.01B 7.66M 6.64M 6.21M 5.67M 10.67M 731M 10.85M 72.87M 28.55M 366M 28.76M 28.13M 1.22B
Net income -94.48M -81.88M -76.65M -69.94M -132M -9.01B -134M -899M -352M -4.51B -355M -347M -15.05B -91.16M -79M -73.95M -67.48M -127M -8.69B -129M -867M -340M -4.35B -342M -335M -14.52B
Net Debt - -
Logo Precision BioSciences, Inc.
Precision BioSciences, Inc. is a clinical-stage gene editing company dedicated to improving life (DTIL) with its proprietary ARCUS genome editing platform. Using ARCUS, the Company’s pipeline is comprised of in vivo gene editing candidates designed to deliver cures for a range of genetic and infectious diseases. The ARCUS platform is used to develop in vivo gene editing therapies for gene edits, including gene insertion, elimination, and excision. The Company's in vivo gene editing pipeline programs include PBGENE-HBV, PBGENE-3243, PBGENE-DMD, PBGENE-LIVER, PBGENE-CNS, PBGENE-NVS and iECURE-OTC. PBGENE-HBV is its lead in vivo gene editing program designed to eliminate cccDNA, the key source of replicating hepatitis B virus (HBV) and inactivating integrated HBV DNA in hepatocytes. Its PBGENE-3243 program is a first of its kind potential treatment for m.3243 associated mitochondrial disease. The Company's iECURE-OTC program is developed in partnership with iECURE, Inc.
Employees
67
Date Price Change Volume
12/08/26 $7.660 +2.00% 46,348
11/08/26 $7.510 +0.67% 345,173
10/08/26 $7.460 -0.40% 192,067
07/08/26 $7.490 +0.94% 240,108
06/08/26 $7.420 -0.67% 328,717
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
5
Last Close Price
7.510USD
Average target price
29.40USD
Spread / Average Target
+291.48%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. DTIL Stock